Report an error   


Submitted: 09 May 2017 Modified: 06 June 2017
HERDIN Record #: PCHRD17050915385212

Rivastigmine: The advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.

1Stephen Christopher ,
2Ananda Krishna Karanam ,
3 Kyung Won Park,
4Encarnita Ampil ,
5 Irene Looi,
6Vorapun Senanarong ,
7Ming-Chyi Pai,
8Nagaendran Kandiah

Abstract

Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition with rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD). Unlike donepezil and galantamine that selectively inhibit acetylcholinesterase (AChE; EC 3.1.1.7), rivastigmine is a unique cholinesterase inhibitor with both AChE and butyrylcholinesterase (BuChE; EC 3.1.1.8) inhibitory activity. Rivastigmine is also available as transdermal patch that has been approved by the US Food and Drug Administration for the treatment of mild, moderate, and severe AD as well as mild-to-moderate PDD. In this review, we explore the role of BuChE inhibition in addition to AChE inhibition with rivastigmine in the outcomes of cognition, global function, behavioral symptoms, and activities of daily living. Additionally, we review the evidence supporting the use of dual AChE

1.
Publication Type:
Journal
Title:
Clinical Interventions in Agin
Publication Date:
April 2018
Volume:
12
Page(s):
697–707.
Publisher:
Auckland : Dove Medical Press

LocationCall NumberAvailable FormatAvailability
U.S. National Library of Medicine: PubMed/Medline Fulltext External Link (View)